Document:

Exhibit 10.1

 

SUBSCRIPTION AGREEMENT

 

DarioHealth Corp.

8 HaTokhen Street

Caesarea Industrial Park

Israel 3088900

 

Ladies and Gentlemen:

 

Subscription.
The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from DarioHealth
Corp., a Delaware corporation (the “Company”), shares of common stock, par value $0.0001 (“Common Stock”
or “Common Shares”), issued at a price per share equal to the “Minimum Price” (as defined in Nasdaq Rule 5635(d),
rounded down to the nearest whole share (i.e., the lesser of (i) the Nasdaq official closing price of the Company’s
Common Stock on Nasdaq.com immediately preceding the signing of the applicable binding agreements for each Closing) or (ii) the
average Nasdaq official closing price of the Company’s Common Stock on Nasdaq.com for the five trading days immediately preceding
the signing of the applicable binding agreements for each Closing. In addition, the Company is also offering to certain purchasers,
in lieu of Common Shares, pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”), with
the purchase price of each Pre-Funded Warrant equal to the Minimum Price applicable for the closing in which the Pre-Funded Warrants
are issued, minus $0.0001, and the exercise price of each Pre-Funded Warrants will be $0.0001 per share. Depending on the context,
any reference to “Common Shares” in this Subscription Agreement shall include “Pre-Funded Warrants.” The
minimum investment amount for each purchaser participating in the Offering is $250,000, which minimum investment may be waived
at the discretion of the Company and the Placement Agent. The Common Shares and Pre-Funded Warrants being sold in the Offering
(as defined below), are as fully described in the Memorandum (as defined below). This Subscription Agreement (this “Subscription
Agreement”) is one in a series of similar subscription agreements (collectively, the “Subscription Agreements”)
entered into pursuant to the Offering.

 

1.             The
Offering. This subscription is submitted to you in accordance with and subject to the terms and conditions described in this
Subscription Agreement and the Confidential Private Placement Memorandum of the Company dated July __, 2020, as amended or
supplemented from time to time, including all attachments, schedules and exhibits thereto (the “Memorandum”), relating
to the offering (the “Offering”) by the Company of a minimum of $10,000,000 of Common Shares (the “Minimum Offering
Amount”), and up to a maximum of $20,000,000 of Common Shares (the “Maximum Offering Amount”), with an over-allotment
amount of up to $10,000,000 of Common Shares (the “Over-Allotment Amount”). SternAegis Ventures, through Aegis Capital
Corp., (“SternAegis”), has been engaged as exclusive placement agent in connection with the Offering (sometimes referred
to as the “Placement Agent”). The terms of the Offering are more completely described in the Memorandum and such terms
are incorporated herein in their entirety.

 

    	 	 1	 

     

    

 

2.             Deliveries
and Payment; Escrow of Funds. Simultaneously with the execution hereof, the Purchaser shall: (a) deliver to SternAegis
in accordance with the Subscription Instructions attached hereto, (i) one (1) completed and executed Omnibus Signature
Page to this Subscription Agreement and the Registration Rights Agreement (page 15), (ii) a completed Accredited
Investor Certification (pages 17-18), (iii) a completed Investor Profile (pages 19-20) and (iv) one (1) completed
and executed Tax Certification for U.S. Persons or Non-U.S. Persons, as applicable (beginning on page 22); and (b) make
a wire transfer payment to, “Signature Bank, Escrow Agent for DarioHealth Corp.” in an amount equal to the dollar amount
of Common Shares or Pre-Funded Warrants being purchased. Wire transfer instructions are set forth on page 12 hereof under
the heading “To subscribe for Common Shares in the private offering of DarioHealth Corp.” Such funds will be held for
the Purchaser's benefit in a non-interest-bearing escrow account (the “Escrow Account”) until the earliest to occur
of (a) a closing of the sale of the Minimum Offering Amount or more (the “First Closing”), (b) the rejection
of such subscription, or (c) the termination of the Offering by the Company or the Placement Agent. The Company and the Placement
Agent may continue to offer and sell the Common Shares and conduct additional closings for the sale of additional Common Shares
after the First Closing and until the termination of the Offering.

 

3.            Acceptance
of Subscription. The Purchaser understands and agrees that the Company, in its sole discretion, reserves the right to accept
or reject this or any other subscription for Common Shares, in whole or in part, notwithstanding prior receipt by the Purchaser
of notice of acceptance of this subscription. In furtherance of the foregoing, the Company shall have the right to require potential
subscribers to supply additional information and execute additional documents in a satisfactory manner, which determination shall
be at the sole discretion of the Company, prior to the acceptance of this Subscription Agreement. The Company shall have no obligation
hereunder until the Company shall execute and deliver to the Purchaser an executed copy of this Subscription Agreement. If this
subscription is rejected in whole, the Offering is terminated or the Minimum Offering Amount is not raised, all funds received
from the Purchaser will be returned without interest or offset, and this Subscription Agreement shall thereafter be of no further
force or effect. If this subscription is rejected in part, the funds for the rejected portion of this subscription will be returned
without interest or offset, and this Subscription Agreement will continue in full force and effect to the extent this subscription
was accepted.

 

4.            Representations
and Warranties.

 

The Purchaser hereby
acknowledges, represents, warrants, and agrees as follows:

 

(a)            None
of the Common Shares, the Pre-Funded Warrants or the Common Shares issuable upon the exercise of the Pre-Funded Warrants (the “Pre-Funded
Warrant Shares”) offered pursuant to the Memorandum are registered under the Securities Act of 1933, as amended (the “Securities
Act”), or any state securities laws. The Purchaser understands that the offering and sale of the Common Shares is intended
to be exempt from registration under the Securities Act, by virtue of Section 4(a)(2) thereof and the provisions of Regulation
D (“Regulation D”) as promulgated by the United States Securities and Exchange
Commission (the “SEC”) thereunder, based, in part, upon the representations, warranties and agreements of the
Purchaser contained in this Subscription Agreement.

 

    	 	 2	 

     

    

 

(b)           The
Purchaser understands that, as further described in the Memorandum, the Common Shares and Pre-Funded Warrants being offered may
be sold at one or more closings and the applicable price per share at which the Common Shares is being sold at each closing and
the applicable price per Pre-Funded Warrants is being sold at each closing may vary from closing to closing since such purchase
price will be measured at the time of each Closing. Accordingly, the Purchaser acknowledges the risk that the purchase price of
the Common Shares or Pre-Funded Warrants that it purchases may be higher than the applicable purchase price paid by other investors
who participate in a different closing.

 

(c)           Prior
to the execution of this Subscription Agreement, the Purchaser and the Purchaser’s attorney, accountant, purchaser representative
and/or tax adviser, if any (collectively, the “Advisers”), have received the Memorandum and all other documents requested
by the Purchaser, have carefully reviewed them and understand the information contained therein.

 

(d)           Neither
the SEC nor any state securities commission or other regulatory authority has approved the Common Shares, the Pre-Funded Warrants
or the Pre-Funded Warrant Shares, or passed upon or endorsed the merits of the Offering or confirmed the accuracy or determined
the adequacy of the Memorandum. The Memorandum has not been reviewed by any federal, state or other regulatory authority.

 

(e)           All
documents, records, and books pertaining to the investment in the securities offered pursuant to the Memorandum (including, without
limitation, the Memorandum) have been made available for inspection by such Purchaser and its Advisers, if any.

 

(f)            The
Purchaser and its Advisers, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or
persons acting on behalf of the Company concerning the offering of the securities pursuant to the Memorandum and the business,
financial condition and results of operations of the Company and LabStyle Innovation Ltd. (the “Subsidiary”) and
all such questions have been answered to the full satisfaction of the Purchaser and its Advisers, if any.

 

(g)           In
evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or information
(oral or written) other than as stated in the Memorandum and the Purchaser and its Advisors have had access, through the Memorandum
and/or the EDGAR system, to true and complete copies of the Company’s most recent Annual Report on Form 10-K for the
fiscal year ended December 31, 2019 (the “10-K”) and all other reports filed by the Company pursuant to the Securities
Exchange Act of 1934, as amended, since the filing of the 10-K and prior to the date hereof and have reviewed such filings (the
 “SEC Reports”).

 

(h)           The
Purchaser is unaware of, is in no way relying on, and did not become aware of the Offering through or as a result of, any form
of general solicitation or general advertising including, without limitation, any article, notice, advertisement or other communication
published in any newspaper, magazine or similar media or broadcast over television, radio or the Internet (including, without limitation,
internet “blogs,” bulletin boards, discussion groups and social networking sites) in connection with the Offering and
is not subscribing for the securities being offered pursuant to the Memorandum and did not become aware of the Offering through
or as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by, a person
not previously known to the Purchaser in connection with investments in securities generally.

 

    	 	 3	 

     

    

 

(i)            The
Purchaser has taken no action that would give rise to any claim by any person for brokerage commissions, finders’ fees or
the like relating to this Subscription Agreement or the transactions contemplated hereby (other than commissions to be paid by
the Company to the Placement Agent or as otherwise described in the Memorandum).

 

(j)            The
Purchaser, together with its Advisers, if any, has such knowledge and experience in financial, tax, and business matters, and,
in particular, investments in securities, so as to enable it to utilize the information made available to it in connection with
the Offering to evaluate the merits and risks of an investment in the Common Shares (or the Pre-Funded Warrants, if applicable)
and the Company and to make an informed investment decision with respect thereto.

 

(k)            The
Purchaser is not relying on the Company, the Placement Agent or any of their respective employees or agents with respect to the
legal, tax, economic and related considerations of an investment in the Company, and the Purchaser has relied on the advice of,
or has consulted with, only its own Advisers.

 

(l)            The
Purchaser is acquiring the securities being offered pursuant to the Memorandum solely for such Purchaser’s own account for
investment purposes only and not with a view to or intent of resale or distribution thereof, in whole or in part. The Purchaser
has no agreement or arrangement, formal or informal, with any person to sell or transfer all or any part of the securities being
offered pursuant to the Memorandum, and the Purchaser has no plans to enter into any such agreement or arrangement.

 

(m)          The
Purchaser must bear the substantial economic risks of the investment in the securities being offered pursuant to the Memorandum
indefinitely because none of the Common Shares, Pre-Funded Warrants or Pre-Funded Warrant Shares may be sold, hypothecated or otherwise
disposed of unless subsequently registered under the Securities Act and applicable state securities laws or an exemption from such
registration is available. Legends shall be placed on the Common Shares, Pre-Funded Warrants and Pre-Funded Warrant Shares to the
effect that they have not been registered under the Securities Act or applicable state securities laws and appropriate notations
thereof will be made in the Company’s stock books. Stop transfer instructions will be placed with the Company’s transfer
agent. The Company has agreed that purchasers of the Common Shares or Pre-Funded Warrants will have, with respect to the Common
Stock or the Pre-Funded Warrants Shares, as applicable, the registration rights described in the Memorandum. Notwithstanding such
registration rights, there can be no assurance that there will be any market for resale of the foregoing securities, nor can there
be any assurance that such securities will be freely transferable at any time in the foreseeable future.

 

(n)           The
Purchaser has adequate means of providing for such Purchaser’s current financial needs and foreseeable contingencies and
has no need for liquidity from its investment in the Common Shares or Pre-Funded Warrants for an indefinite period of time.

 

(o)           The
Purchaser is aware that an investment in the Common Shares and the Pre-Funded Warrants, as applicable, is high risk, involving
a number of very significant risks and has carefully read and considered the matters set forth under the caption “Risk Factors”
in the Memorandum and in the SEC Reports, and, in particular, acknowledges that the Company with its Subsidiary is a development
stage company which has only recently entered the commercialization stage of its technology, has had significant operating losses
since inception, limited revenues from operations to date, and are engaged in highly competitive businesses.

 

    	 	 4	 

     

    

 

(p)           The
Purchaser meets the requirements of at least one of the suitability standards for an “accredited investor” as that
term is defined in Regulation D and as set forth on the Accredited Investor Certification contained herein.

 

(q)           The
Purchaser (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority
to execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions
hereof and thereof; (ii) if a corporation, partnership, or limited liability company or partnership, or association, joint
stock company, trust, unincorporated organization or other entity, represents that such entity was not formed for the specific
purpose of acquiring the securities offered pursuant to the Memorandum, such entity is duly organized, validly existing and in
good standing under the laws of the state of its organization, the consummation of the transactions contemplated hereby is authorized
by, and will not result in a violation of state law or its charter or other organizational documents, such entity has full power
and authority to execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry
out the provisions hereof and thereof and to purchase and hold the securities offered pursuant to the Memorandum, the execution
and delivery of this Subscription Agreement has been duly authorized by all necessary action, this Subscription Agreement has been
duly executed and delivered on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if
executing this Subscription Agreement in a representative or fiduciary capacity, represents that it has full power and authority
to execute and deliver this Subscription Agreement in such capacity and on behalf of the subscribing individual, ward, partnership,
trust, estate, corporation, or limited liability company or partnership, or other entity for whom the Purchaser is executing this
Subscription Agreement, and such individual, partnership, ward, trust, estate, corporation, or limited liability company or partnership,
or other entity has full right and power to perform pursuant to this Subscription Agreement and make an investment in the Company,
and represents that this Subscription Agreement constitutes a legal, valid and binding obligation of such entity. The execution
and delivery of this Subscription Agreement will not violate or be in conflict with any order, judgment, injunction, agreement
or controlling document to which the Purchaser is a party or by which it is bound.

 

(r)            The
Purchaser and the Advisers, if any, have had the opportunity to obtain any additional information, to the extent the Company has
such information in their possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy
of the information contained in the Memorandum and all documents received or reviewed in connection with the purchase of the securities
and have had the opportunity to have representatives of the Company provide them with such additional information regarding the
terms and conditions of this particular investment and the financial condition, results of operations, and business of the Company
and the Subsidiary deemed relevant by the Purchaser or the Advisers, if any, and all such requested information, to the extent
the Company has such information in their possession or could acquire it without unreasonable effort or expense, has been provided
to the full satisfaction of the Purchaser and the Advisers, if any.

 

    	 	 5	 

     

    

 

(s)           Any
information which the Purchaser has heretofore furnished or is furnishing herewith to the Company or the Placement Agent is complete
and accurate and may be relied upon by the Company and the Placement Agent in determining the availability of an exemption from
registration under federal and state securities laws in connection with the offering of securities as described in the Memorandum.
The Purchaser further represents and warrants that it will notify and supply corrective information to the Company and the Placement
Agent immediately upon the occurrence of any change therein occurring prior to the Company's issuance of the securities being offered
and sold pursuant to the Memorandum.

 

(t)            The
Purchaser has significant prior investment experience, including investment in non-listed and non-registered securities. The Purchaser
is knowledgeable about investment considerations in development-stage companies with limited operating histories. The Purchaser
has a sufficient net worth to sustain a loss of its entire investment in the Company in the event such a loss should occur. The
Purchaser's overall commitment to investments which are not readily marketable is not excessive in view of the Purchaser’s
net worth and financial circumstances and the purchase of the securities being offered and sold pursuant to the Memorandum will
not cause such commitment to become excessive. Investment in the Company as contemplated by this Subscription Agreement is suitable
for the Purchaser.

 

(u)           The
Purchaser is satisfied that the Purchaser has received adequate information with respect to all matters which it or the Advisers,
if any, consider material to its decision to make an investment in the Company in the securities being offered and sold pursuant
to the Memorandum as contemplated by this Subscription Agreement.

 

(v)           The
Purchaser acknowledges that any estimates or forward-looking statements or projections included in the Memorandum were prepared
by the Company in good faith but that the attainment of any such projections, estimates or forward-looking statements cannot be
guaranteed by the Company or the Subsidiary and should not be relied upon.

 

(w)           The
Purchaser acknowledges that it has been provided with, and has reviewed, Aegis’ Regulation Best Interest Form CRS and
Disclosure Supplement in the form of Exhibit A hereto (the “BI CRS and Disclosure Supplement”) and has had
a reasonable opportunity to ask questions of and receive answers from a person or persons acting on behalf of Aegis concerning
the BI CRS and Disclosure Supplement.

 

(x)            No
oral or written representations have been made, or oral or written information furnished, to the Purchaser or the Advisers, if
any, in connection with the Offering which are in any way inconsistent with the information contained in the Memorandum.

 

(y)           Within
five (5) days after receipt of a request from the Company or the Placement Agent, the Purchaser will provide such information
and deliver such documents as may reasonably be necessary to comply with any and all laws and ordinances to which the Company or
the Placement Agent is subject.

 

(z)           The
Purchaser's substantive relationship with either the Company, the Placement Agent or subagent through which the Purchaser is subscribing
for Common Shares predates such Placement Agent's or such subagent's contact with the Purchaser regarding an investment in the
Common Shares.

 

    	 	 6	 

     

    

 

(aa)         THE
SECURITIES OFFERED HEREBY (INCLUDING THE PRE-FUNDED WARRANTS AND THE PRE-FUNDED WARRANT SHARES) HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM
THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. SUCH SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE
AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. SUCH SECURITIES HAVE NOT BEEN RECOMMENDED, APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE
SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE
MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE MEMORANDUM OR THIS SUBSCRIPTION AGREEMENT. ANY REPRESENTATION TO THE
CONTRARY IS UNLAWFUL.

 

(bb)         In
making an investment decision in the Company, investors must rely on their own examination of the Company, the Subsidiary and the
terms of the Offering, including the merits and risks involved. The Purchaser should be aware that it will be required to bear
the financial risks of investment in the Company and the securities being offered and sold pursuant to the Memorandum for an indefinite
period of time.

 

(cc)          (For
ERISA plans only) The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary has been informed
of and understands the Company’s investment objectives, policies and strategies, and that the decision to invest “plan
assets” (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require diversification
of plan assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (a) is responsible for the decision
to invest in the Company; (b) is independent of the Company or any of its affiliates; (c) is qualified to make such investment
decision; and (d) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation
of the Company or any of its affiliates.

 

(dd)        The
Purchaser should check the Office of Foreign Assets Control (“OFAC”) website at <http://www.treas.gov/ofac>
before making the following representations. The Purchaser represents that the amounts invested by it in the Company in the
Offering were not and are not directly or indirectly derived from activities that contravene federal, state or international laws
and regulations, including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by
OFAC prohibit, among other things, the engagement in transactions with, and the provision of services to, certain foreign countries,
territories, entities and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found
on the OFAC website at <http://www.treas.gov/ofac>. In addition, the programs administered by OFAC (the “OFAC Programs”)
prohibit dealing with individuals1 or entities in
certain countries regardless of whether such individuals or entities appear on the OFAC lists.

 

 

1
These individuals include specially designated nationals, specially designated narcotics traffickers and other parties
subject to OFAC sanctions and embargo programs.

 

    	 	 7	 

     

    

 

(ee)         To
the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by
the Purchaser; (3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser;
or (4) any person for whom the Purchaser is acting as agent or nominee in connection with this investment is a country, territory,
individual or entity named on an OFAC list, or a person or entity prohibited under the OFAC Programs. Please be advised that the
Company may not accept any amounts from a prospective investor if such prospective investor cannot make the representation set
forth in the preceding paragraph. The Purchaser agrees to promptly notify the Company and the Placement Agent should the Purchaser
become aware of any change in the information set forth in these representations. The Purchaser understands and acknowledges that,
by law, the Company may be obligated to “freeze the account” of the Purchaser, either by prohibiting additional subscriptions
from the Purchaser, declining any redemption requests and/or segregating the assets in the account in compliance with governmental
regulations, and the Placement Agent may also be required to report such action and to disclose the Purchaser’s identity
to OFAC. The Purchaser further acknowledges that the Company may, by written notice to the Purchaser, suspend the redemption rights,
if any, of the Purchaser if the Company reasonably deems it necessary to do so to comply with anti-money laundering regulations
applicable to the Company and the Placement Agent or any of the Company’s other service providers. These individuals include
specially designated nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and embargo
programs.

 

(ff)           To
the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by
the Purchaser; (3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser;
or (4) any person for whom the Purchaser is acting as agent or nominee in connection with this investment is a senior foreign
political figure,2 or any immediate family3
member or close associate4 of a senior
foreign political figure, as such terms are defined in the footnotes below.

 

(gg)         If
the Purchaser is affiliated with a non-U.S. banking institution (a “Foreign Bank”), or if the Purchaser receives deposits
from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser represents
and warrants to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address, in a
country in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records
related to its banking activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the
Foreign Bank to conduct banking activities; and (4) the Foreign Bank does not provide banking services to any other Foreign
Bank that does not have a physical presence in any country and that is not a regulated affiliate.

 

 

2 A “senior foreign political
figure” is defined as a senior official in the executive, legislative, administrative, military or judicial branches of
a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of
a foreign government-owned corporation. In addition, a “senior foreign political figure” includes any corporation,
business or other entity that has been formed by, or for the benefit of, a senior foreign political figure.

 

3
“Immediate family” of a senior foreign political figure typically includes the figure’s parents,
siblings, spouse, children and in-laws.

 

4
A “close associate” of a senior foreign political figure is a person who is widely and publicly known
to maintain an unusually close relationship with the senior foreign political figure, and includes a person who is in a position
to conduct substantial domestic and international financial transactions on behalf of the senior foreign political figure.

 

    	 	 8	 

     

    

 

5.             Indemnification.
The Purchaser agrees to indemnify and hold harmless the Company the Subsidiary, the Placement Agent (including its selected dealers,
if any), and their respective officers, directors, employees, agents, control persons and affiliates from and against all losses,
liabilities, claims, damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred
in investigating, preparing or defending against any litigation commenced or threatened) based upon or arising out of any actual
or alleged false acknowledgment, representation or warranty, or misrepresentation or omission to state a material fact, or breach
by the Purchaser of any covenant or agreement made by the Purchaser herein or in any other document delivered in connection with
this Subscription Agreement. Each Purchaser’s obligation to indemnify shall be individual, not joint and several, and in
no event shall the liability of any Purchaser hereunder be greater in amount than the dollar amount of the net proceeds received
by such Purchaser upon the sale of the Shares acquired pursuant to this Subscription Agreement.

 

6.             Irrevocability;
Binding Effect. The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the Purchaser,
except as required by applicable law, and that this Subscription Agreement shall survive the death or disability of the Purchaser
and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal
representatives, and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder shall
be joint and several and the agreements, representations, warranties, and acknowledgments herein shall be deemed to be made by
and be binding upon each such person and such person's heirs, executors, administrators, successors, legal representatives, and
permitted assigns.

 

7.             Modification.
This Subscription Agreement shall not be modified or waived except by an instrument in writing signed by the party against whom
any such modification or waiver is sought.

 

8.             Immaterial
Modifications to the Registration Rights Agreement. The Company may, at any time prior to the First Closing, modify the Registration Rights
Agreement if necessary to clarify any provision therein, without first providing notice or obtaining prior consent of the Purchaser,
if, and only if, such modification is not material in any respect.

 

9.             Notices.
Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be deemed effectively
given: (a) upon personal delivery to the party notified, (b) when sent by confirmed email or facsimile if sent during
normal business hours of the recipient, if not confirmed, then on the next business day, (c) five days after having been sent
by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. The Company and the Purchaser
hereby consent to the delivery of communications and notices to such parties at their respective address, email or facsimile number
set forth on the signature page hereto, or to such other address as such party shall have furnished in writing in accordance
with the provisions of this Section 10.

 

10.           Assignability.
This Subscription Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser
and the transfer or assignment of the any of the Common Shares, the Pre-Funded Warrants or Pre-Funded Warrant Shares shall be made
only in accordance with all applicable laws.

 

    	 	 9	 

     

    

 

11.           Applicable
Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable
to contracts to be wholly-performed within said State.

 

12.           Arbitration.
The parties agree to submit all controversies to arbitration in accordance with the provisions set forth below and understand that:

 

(a)           Arbitration
is final and binding on the parties.

 

(b)           The
parties are waiving their right to seek remedies in court, including the right to a jury trial.

 

(c)           Pre-arbitration
discovery is generally more limited and different from court proceedings.

 

(d)           The
arbitrator’s award is not required to include factual findings or legal reasoning and any party’s right to appeal or
to seek modification of rulings by arbitrators is strictly limited.

 

(e)           The
panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry.

 

(f)            All
controversies which may arise between the parties concerning this Subscription Agreement shall be determined by arbitration pursuant
to the rules then pertaining to the Financial Industry Regulatory Authority, Inc. (“FINRA”) in New York City,
New York. Judgment on any award of any such arbitration may be entered in the Supreme Court of the State of New York or in any
other court having jurisdiction of the person or persons against whom such award is rendered. Any notice of such arbitration or
for the confirmation of any award in any arbitration shall be sufficient if given in accordance with the provisions of this Agreement.
The parties agree that the determination of the arbitrators shall be binding and conclusive upon them.

 

13.           Blue
Sky Qualification. The purchase of the securities under this Subscription Agreement is expressly conditioned upon the exemption
from qualification of the offer and sale of such securities from applicable federal and state securities laws. The Company shall
not be required to qualify this transaction under the securities laws of any jurisdiction and, should qualification be necessary,
the Company shall be released from any and all obligations to maintain its offer, and may rescind any sale contracted, in the jurisdiction.

 

14.           Use
of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter,
singular or plural as the identity of the person or persons referred to may require.

 

15.           Confidentiality.
The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company or the
Subsidiary, not otherwise properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate
or disclose, except as may be required by law or for the performance of this Agreement, or use to the detriment of the Company
or the Subsidiary or for the benefit of any other person or persons, or misuse in any way, any confidential information of the
Company or the Subsidiary, including any scientific, technical, trade or business secrets of the Company or the Subsidiary and
any scientific, technical, trade or business materials that are treated by the Company or the Subsidiary as confidential or proprietary,
including, but not limited to, ideas, discoveries, inventions, developments and improvements belonging to the Company or the Subsidiary
and confidential information obtained by or given to the Company or the Subsidiary about or belonging to third parties.

 

    	 	 10	 

     

    

 

16.           Miscellaneous.

 

(a)           This
Subscription Agreement, together with the Registration Rights Agreement, constitute the entire agreement between the Purchaser
and the Company with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings,
if any, relating to the subject matter hereof. The terms and provisions of this Subscription Agreement may be waived, or consent
for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or
provisions.

 

(b)           The
representations and warranties of the Purchaser made in this Subscription Agreement shall survive the execution and delivery hereof
and delivery of the securities.

 

(c)           Each
of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others
engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the
transactions contemplated hereby are consummated.

 

(d)           This
Subscription Agreement may be executed in one or more counterparts each of which shall be deemed an original, but all of which
shall together constitute one and the same instrument.

 

(e)            Each
provision of this Subscription Agreement shall be considered separable and, if for any reason any provision or provisions hereof
are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair the operation of or
affect the remaining portions of this Subscription Agreement.

 

(f)            Paragraph
titles are for descriptive purposes only and shall not control or alter the meaning of this Subscription Agreement as set forth
in the text.

 

(g)           The
Purchaser understands and acknowledges that there may be multiple closings for this Offering.

 

17.           Omnibus
Signature Page. This Subscription Agreement is intended to be read and construed in conjunction with the Registration Rights
Agreement pertaining to the issuance by the Company of the securities to subscribers pursuant to the Memorandum. Accordingly, pursuant
to the terms and conditions of this Subscription Agreement and such related agreements it is hereby agreed that the execution by
the Purchaser of this Subscription Agreement, in the place set forth herein, shall constitute agreement to be bound by the terms
and conditions hereof and the terms and conditions of the Registration Rights Agreement, with the same effect as if each of such
separate but related agreement were separately signed.

 

    	 	 11	 

     

    

 

 

 

18.            Book
Entry Registration of the Securities. The Company will issue the Common Shares by registering them in book entry form with
the Company's transfer agent in Purchaser’s name and the applicable restrictions will be noted in the records of the Company's
transfer agent and in the book entry system, except for investments made via custodian accounts such as Pensions and IRA's in which
case physical certificates evidencing the Common Shares will be issued if so requested. Any Pre-Funded Warrants sold in the Offering
will be issued in certificated form.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK]

 

    12

     

    

 

PRIVATE PLACEMENT OFFERING OF 

DarioHealth
Corp.

 

SUBSCRIPTION INSTRUCTIONS

 

To
subscribe for Common Shares in the private offering of DarioHealth Corp.:

 

		1.	Date and Fill in the dollar amount of Common Shares and/or Pre-Funded Warrants being purchased
and Complete and Sign the Omnibus Signature Page to the Subscription Agreement (page 15).

 

		2.	Initial the Accredited Investor Certification page attached to the Subscription Agreement
(pages 17-18).

 

		3.	Complete and return the Investor Profile (pages 19-20).

 

		4.	Complete and Sign the Tax Certification for U.S. Persons or Non-U.S. Persons, as applicable
(beginning on page 22).

 

		5.	Fax
                                         or e-mail all forms to Edward Shadek at 646-502-2444 / EShadek@sternaegis.com.

 

		6.	Please wire funds directly to the escrow account pursuant to the following instructions (unless other arrangements have
been made); checks cannot be accepted:

 

Bank Name: Signature Bank

 

Bank Address: 950 Third Avenue, NY, NY 10022 (IF wiring banker
requests this info)

 

ABA Number: 026013576

 

SWIFT CODE: SIGNUS33

 

A/C
Name: Signature Bank, as Agent for DarioHealth Corp.

 

DarioHealth
Corp. Address (if requested): 8 HaTokhen Street, Caesarea Industrial Park

Israel 3088900

 

A/C
Number: 1503850164

 

REF. outgoing wire with the following information

 

	FBO:	Investor Name	 
	 	 
	SSN/TIN	 
	 	 
	Address	 

 

    13

     

    

 

ANTI MONEY LAUNDERING REQUIREMENTS

 

	
        The USA PATRIOT Act

         
	What is money laundering?	How big is the problem and why is it important?
	
         

        The USA PATRIOT Act is designed to detect, deter, and punish
        terrorists in the United States and abroad. The Act imposes new anti-money laundering requirements on brokerage firms and financial
        institutions. Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money laundering
        programs.

         

        To help you understand these efforts, we want to provide you
        with some information about money laundering and the Placement Agent’s efforts to implement the USA PATRIOT Act.
	
         

        Money laundering is the process of disguising illegally obtained
        money so that the funds appear to come from legitimate sources or activities. Money laundering occurs in connection with a wide
        variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.
	
         

        The use of the U.S. financial system by criminals to facilitate
        terrorism or other crimes could well taint our financial markets. According to the U.S. State Department, one recent estimate puts
        the amount of worldwide money laundering activity at $1 trillion a year.

 

	What the Placement Agent is required to do to help eliminate money laundering?
	
         

        Under new rules required by the USA PATRIOT Act, the Placement
        Agent’s anti-money laundering program must designate a special compliance officer, set up employee training, conduct independent
        audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance with the new laws.
	
         

        As part of the Placement Agent’s required program, it
        may ask you to provide various identification documents or other information. Until you provide the information or documents that
        the Placement Agent needs, it may not be able to effect any transactions for you.

 

    14

     

    

 

DarioHealth
Corp. 

OMNIBUS SIGNATURE PAGE TO THE 

SUBSCRIPTION AGREEMENT AND Registration
Rights AGREEMENT

 

Purchaser
hereby elects to subscribe under the Subscription Agreement for a total of $__________ of Common Shares and/or Pre-Funded Warrants
(only if indicated below) (NOTE: to be completed by Purchaser) and, by execution and delivery hereof, Purchaser hereby
executes the Subscription Agreement and agrees to be bound by the terms and conditions of the Subscription Agreement and the Registration
Rights Agreement.

 

 ̈  Check here only if Purchaser is purchasing
a portion of Pre-Funded Warrants. Pre-Funded Warrants can only be purchased by certain investors who have made prior arrangements
with the Company and the Placement Agent. Please indicate the dollar amount of Pre-Funded Warrants being purchased $__________.

 

 

If the Purchaser is an INDIVIDUAL, and
if purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY:

 

	 	 	 
	Print
    Name(s)	 	Social
    Security Number(s)
	 	 	 
	 	 	 
	Signature(s) of
    Purchaser(s)	 	Signature
	 	 	 
	 	 	 
	Date	 	Address

 

If the Purchaser is a PARTNERSHIP, CORPORATION,
LIMITED LIABILITY COMPANY or TRUST:

 

	 	 	 
	Name of Entity	 	Federal Taxpayer
	 	 	Identification Number
		 	 
	 	 	 
	By:	 	 	 
	 	Name:	 	State of Organization
	 	Title:	 	 
	 	 	 
	 	 	 
	Date     	 	Address
	 	 	 
	 	 	 
	Fax Number	 	Email Address

 

[signature page continues on following
page]

 

    15

     

    

 

DarioHealth
Corp. 

OMNIBUS SIGNATURE PAGE TO THE 

SUBSCRIPTION AGREEMENT AND Registration
Rights AGREEMENT 

[Continued]

 

	DarioHealth Corp.	 	AEGIS CAPITAL CORP.
	 	 	 
	 	 	 
	By:	 	 	By:	 
	 	Authorized Officer	 	 	Authorized Officer

 

    16

     

    

 

DarioHealth
Corp. 

ACCREDITED INVESTOR CERTIFICATION 

 

For Individual Investors Only 

(all Individual Investors must INITIAL
where appropriate):

 

Initial
_______   I have an individual net worth, or joint net worth with my spouse, as of the date hereof in excess of $1
million. For purposes of calculating net worth under this category, (i) the undersigned’s primary residence shall not
be included as an asset, (ii) indebtedness that is secured by the undersigned’s primary residence, up to the estimated
fair market value of the primary residence at the time of the sale of securities, shall not be included as a liability, (iii) to
the extent that the indebtedness that is secured by the primary residence is in excess of the fair market value of the primary
residence, the excess amount shall be included as a liability, and (iv) if the amount of outstanding indebtedness that is
secured by the primary residence exceeds the amount outstanding 60 days prior to the execution of this Subscription Agreement,
other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability.

 

Initial
_______   I have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly
with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.

 

Initial
_______   I am a director or executive officer of DarioHealth Corp.

 

For Non-Individual Investors 

(all Non-Individual Investors must INITIAL
where appropriate):

 

Initial
_______   The investor certifies that it is a partnership, corporation, limited liability company or business trust
that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above.

 

Initial
_______   The investor certifies that it is a partnership, corporation, limited liability company or any organization
described in Section 501(c)(3) of the Internal Revenue Code, Massachusetts or similar business trust that has total assets
of at least $5,000,000f and was not formed for the purpose of investing the Company.

 

Initial
_______   The investor certifies that it is an employee benefit plan within the meaning of the Employee Retirement
Income Security Act of 1974, whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a
bank, savings and loan association, insurance company or registered investment adviser.

 

Initial
_______   The investor certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the
date of this Agreement.

 

    17

     

    

 

Initial
_______   The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are
made solely by persons who meet either of the criteria for Individual Investors.

 

Initial
_______   The investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution
acting in its individual or fiduciary capacity.

 

Initial
_______   The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange
Act of 1934.

 

Initial
_______   The investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue
Code with total assets exceeding $5,000,000 and not formed for the specific purpose of investing in the Company.

 

Initial
_______   The investor certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific
purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in financial
and business matters that he is capable of evaluating the merits and risks of the prospective investment.

 

Initial
_______   The investor certifies that it is a plan established and maintained by a state or its political subdivisions,
or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.

 

Initial
_______   The investor certifies that it is an insurance company as defined in §2(13) of the Securities Act, or
a registered investment company.

 

Initial
_______  An investment company registered under the Investment Company Act of 1940 or a business development company
as defined in Section 2(a)(48) of that Act.

 

Initial
_______   A Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or
(d) of the Small Business Investment Act of 1958.

 

Initial
_______   A private business development company as defined in Section 202(a)(22) of the Investment Advisers Act
of 1940.

 

    18

     

    

 

DarioHealth
Corp. 

Investor
Profile (Must be completed by Investor)

 

Section A - Personal Investor
Information

 

For All Purchasers

 

Certificate Title: ______________________________________________________________________

 

Individual(s) executing this subscription: ___________________________________________________

 

Social Security Number(s) for all signatories:
________________________________

 

Entity
Federal I.D. Number: _____________________________________________

 

Date(s) of Birth: ______________

 

Marital Status: _______________

 

Years Investment Experience: ______________

 

Aegis Capital Acct Executive or Outside Broker/Dealer: ______
/Aegis Rep 3-Digit I.D._____/Aegis Acct #_______

 

Check if you are a FINRA member or affiliate of a FINRA member
firm:  ̈

 

Check Investment Objective(s) (See
definitions on following page):  ̈ Preservation of Capital  ̈
Income  ̈ Capital Appreciation  ̈
Trading Profits  ̈ Speculation  ̈
Other (please specify)

 

The source of funds for this investment is my personal or
my entity's assets   ̈ Yes    ̈
No

 

For Purchasers as Individual or as Joint Tenants, Tenants
in Common, and Community Property

 

Annual Income(s): ___________________

 

Liquid Net Worth(s):__________________

 

Net Worth(s) (excluding value of primary residence): ________________

 

Select Tax Bracket(s): ____ 15% or below ____ 25% - 27.5% ____
Over 27.5%

 

For All Purchasers, by the Primary Contact

 

Home Street Address: _________________________________________________________________

 

Home City, State & Zip Code: ___________________________________________________________

 

Home Phone: __________________ Home Fax: ________________Home
Email: __________________

 

Employer: ___________________________________

 

Type of Business: _____________________________

 

Employer Street Address: _______________________________________________________________

 

Employer City, State & Zip Code: _________________________________________________________

 

Bus. Phone: ____________________Bus. Fax: ___________________Bus.
Email: __________________

 

For All Purchasers

 

If you are a United States citizen,
please list the number and jurisdiction of issuance of any other government-issued document evidencing residence and bearing a
photograph or similar safeguard (such as a driver’s license or passport), and provide a photocopy of each of the documents
you have listed.

 

If you are NOT a United
States citizen, for each jurisdiction of which you are a citizen or in which you work or reside, please list (i) your
passport number and country of issuance or (ii) alien identification card number AND (iii) number and country
of issuance of any other government-issued document evidencing nationality or residence and bearing a photograph or similar safeguard,
and provide a photocopy of each of these documents you have listed.

 

Government-Issued Identification Document Number(s) and
Jurisdiction(s):___________________

 

In addition, please provide a legible
photocopy of your Identification Document(s) with your subscription

 

    19

     

    

 

Section B – Investor Representations 

(Please Check Each)

 

  ̈
I understand that an investment in the securities is speculative and this characterization is consistent with my overall
investment objectives. I seek a significant increase in the principal value of my investments and are willing to accept a
corresponding greater degree of risk by investing in securities that have historically demonstrated a high degree of risk of
loss of principal value to pursue this objective.

 

  ̈
I understand that an investment in the securities has the potential to be a long term investment. It is consistent with my
investment objectives and my financial situation that a return on an investment in the securities, if there is a return at
all, may take three to five years or longer. I have no current or anticipated need for liquidity in my investment in the
securities that would require me to liquidate my investment over a shorter period of time and I can afford a loss of my
entire investment in the securities.

 

  ̈
I confirm that I have reviewed Aegis’ Regulation Best Interest Form CRS and Disclosure Supplement in the form of
Exhibit A hereto (the “BI CRS and Disclosure Supplement”) and have had a reasonable opportunity to ask
questions of and receive answers from a person or persons acting on behalf of Aegis concerning the BI CRS and Disclosure
Supplement.

 

Section C – Securities
Delivery Instructions

 

 ̈
 Please deliver securities to the Employer Address listed
in Section A.

 

 ̈
 Please deliver securities to the Home Address listed in
Section A.

 

 ̈
Please deliver securities to the following address: _________________________________

 

Section D –Wire Transfer
Instructions

 

 ̈
I will wire funds from my outside
account according to the “Subscription Instructions” Page.

 

 ̈
 I will wire funds from my Aegis Capital
Account.

 

 ̈
The funds for this investment are rolled
over, tax deferred from __________ within the allowed 60 day window.

 

	 	 	 
	Investor Signature	Date
	 	 
	 	 	 
	Investor Signature	Date
	 	 

 

    20

     

    

 

Investment
Objectives: The typical investment listed with each objective are only some examples of the kinds of investments that
have historically been consistent with the listed objectives. However, neither the Company nor the Placement Agent can assure that
any investment will achieve your intended objective. You must make your own investment decisions and determine for yourself if
the investments you select are appropriate and consistent with your investment objectives.

 

Neither the Company nor the Placement Agent
assumes responsibility to you for determining if the investments you selected are suitable for you.

 

Preservation
of Capital: An investment objective of Preservation of Capital indicates you seek to maintain the principal value
of your investments and are interested in investments that have historically demonstrated a very low degree of risk of loss of
principal value. Some examples of typical investments might include money market funds and high quality, short-term fixed income
products.

 

Income:
An investment objective of Income indicates you seek to generate income from investments and are interested in investments
that have historically demonstrated a low degree of risk of loss of principal value. Some examples of typical investments might
include high quality, short and medium-term fixed income products, short-term bond funds and covered call options.

 

Capital
Appreciation: An investment objective of Capital Appreciation indicates you seek to grow the principal value
of your investments over time and are willing to invest in securities that have historically demonstrated a moderate to above average
degree of risk of loss of principal value to pursue this objective. Some examples of typical investments might include common stocks,
lower quality, medium-term fixed income products, equity mutual funds and index funds.

 

Trading
Profits: An investment objective of Trading Profits indicates you seek to take advantage of short-term trading
opportunities, which may involve establishing and liquidating positions quickly. Some examples of typical investments might include
short-term purchases and sales of volatile or low priced common stocks, put or call options, spreads, straddles and/or combinations
on equities or indexes. This is a high-risk strategy.

 

Speculation:
An investment objective of Speculation indicates you seek a significant increase in the principal value of your investments
and are willing to accept a corresponding greater degree of risk by investing in securities that have historically demonstrated
a high degree of risk of loss of principal value to pursue this objective. Some examples of typical investments might include lower
quality, long-term fixed income products, initial public offerings, volatile or low priced common stocks, the purchase or sale
of put or call options, spreads, straddles and/or combinations on equities or indexes, and the use of short-term or day trading
strategies.

 

Other:
Please specify.

 

    21Exhibit 10.2

 

Registration
Rights Agreement

 

This Registration Rights
Agreement (this “Agreement”) is made and entered into effective as of _______, 2020 (the “Effective
Date”) between DarioHealth Corp., a Delaware corporation (the “Company”), and the persons who have
executed the signature page(s) hereto (each, a “Purchaser” and collectively, the “Purchasers”).

 

RECITALS:

 

WHEREAS, the Company
is conducting a private placement offering (the “Offering”) of a minimum of $10,000,000 of shares of common
stock, par value $0.0001 (“Common Stock”), issued at the “Minimum Price” (as defined in Nasdaq Rule 5635(d) 
(i.e., the lesser of (i) the Nasdaq official closing price of the Company’s Common Stock on Nasdaq.com immediately preceding
the signing of the applicable binding agreements for each Closing or (ii) the average Nasdaq official closing price of the
Company’s Common Stock on Nasdaq.com for the five trading days immediately preceding the signing of the applicable binding
agreements for each Closing. The shares of Common Stock issued in the Offering is sometimes hereinafter referred to as the “Common
Shares;” and

 

WHEREAS, the Company
is also offering to certain purchasers, pre-funded warrants to purchase shares of Common Stock, in lieu of purchasing Common Shares
(the “Pre-Funded Warrants”), with the purchase price of each Pre-Funded Warrant equal to the Minimum Price applicable
for the closing in which the Pre-Funded Warrants are issued, minus $0.0001, and the exercise price of each Pre-Funded Warrants
will be $0.0001 per share; and

 

WHEREAS, in connection
with the Offering, the Company agreed to provide certain registration rights related to the Common Shares sold in the Offering,
as well as the shares of Common Stock issuable upon the exercise of any Pre-Funded Warrants sold in the Offering, on the terms
set forth herein.

 

Now,
Therefore, in consideration of the mutual promises, representations, warranties, covenants, and conditions set forth herein,
the parties mutually agree as follows:

 

1.            Certain
Definitions. As used in this Agreement, the following terms shall have the following respective meanings:

 

“Agreement”
has the meaning given it in the preamble to this Agreement.

 

“Allowed Delay”
has the meaning given it in Section 2(c)(2) of this Agreement.

 

“Approved
Market” means the Over-the-Counter Bulletin Board, the OTC Markets, Nasdaq Stock Market, the New York Stock Exchange
or the NYSE American.

 

     

     

    

 

“Blackout
Period” means, with respect to a registration, a period, in each case commencing on the day immediately after the Company
notifies the Purchasers that they are required, because of the occurrence of an event of the kind described in Section 3(f) hereof,
to suspend offers and sales of Registrable Securities during which the Company, in the good faith judgment of its board of directors,
determines (because of the existence of, or in anticipation of, any acquisition, financing activity, or other transaction involving
the Company, or the unavailability for reasons beyond the Company’s control of any required financial statements, disclosure
of information which is in its best interest not to publicly disclose, or any other event or condition of similar significance
to the Company) that the registration and distribution of the Registrable Securities to be covered by such Registration Statement,
if any, would be seriously detrimental to the Company or its stockholders and ending on the earlier of (1) the date upon which
the MNPI commencing the Blackout Period is disclosed to the public or ceases to be material and (2) such time as the Company
notifies the selling Holders that the Company will no longer delay such filing of the Registration Statement, recommence taking
steps to make such Registration Statement effective, or allow sales pursuant to such Registration Statement to resume.

 

“Business
Day” means any day of the year, other than a Saturday, Sunday, or other day on which the Commission is required or authorized
to close.

 

“Commission”
or “SEC” means the U.S. Securities and Exchange Commission or any other applicable federal agency at the time
administering the Securities Act.

 

“Common Shares”
has the meaning given it in the preamble to this Agreement.

 

“Common Stock”
means the common stock, par value $0.0001 per share, of the Company and any and all shares of capital stock or other equity securities
of: (i) the Company which are added to or exchanged or substituted for the Common Stock by reason of the declaration of any
stock dividend or stock split, the issuance of any distribution or the reclassification, readjustment, recapitalization or other
such modification of the capital structure of the Company; and (ii) any other corporation, now or hereafter organized under
the laws of any state or other governmental authority, with which the Company is merged, which results from any consolidation or
reorganization to which the Company is a party, or to which is sold all or substantially all of the shares or assets of the Company,
if immediately after such merger, consolidation, reorganization or sale, the Company or the stockholders of the Company own equity
securities having in the aggregate more than 50% of the total voting power of such other corporation.

 

“Company”
has the meaning given it in the preamble to this Agreement.

 

“Effective
Date” has the meaning given it in the preamble to this Agreement.

 

“Effectiveness
Deadline” means the date that is ninety (90) days after the Registration Filing Deadline.

 

“Effectiveness
Period” has the meaning given it in Section 2(a) of this Agreement

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder.

 

“Holder”
means a Purchaser or any permitted transferee or assignee thereof to whom a Purchaser assigns its rights under this Agreement and
who agrees to become bound by the provisions of this Agreement in accordance with Section 6 and any transferee or assignee
thereof to whom a transferee or assignee assigns its rights under this Agreement and who agrees to become bound by the provisions
of this Agreement in accordance with Section 6.

 

    2

     

    

 

“Majority
Holders” means at any time holders of at least a majority of the Registrable Securities.

 

“MNPI”
means material non-public information within the meaning of Regulation FD promulgated under the Exchange Act, which shall, in any
case, include the receipt of the notice pursuant to Section 2(c) and the information contained in such notice.

 

“Piggyback
Registration” means, in any registration of Common Stock as set forth in Section 2(d), the ability of holders of
Registrable Securities to include Registrable Securities in such registration.

 

“Placement
Agent” means Aegis Capital Corp.

 

The terms “register,”
 “registered,” and “registration” refer to a registration effected by preparing and filing
a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration
statement.

 

“Registrable
Securities” means the Common Shares sold in the Offering as well as the shares of Common Stock issuable upon the exercise
of any Pre-Funded Warrants sold in the Offering.

 

“Registration
Filing Date” means the date that is ninety (90) days after the date of the final closing of the Offering.

 

“Registration
Statement” means the registration statement that the Company is required to file pursuant to this Agreement to register
the Registrable Securities.

 

“Rule 144”
means Rule 144 promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such rule.

 

“Rule 415”
means Rule 415 promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, or any similar federal statute promulgated in replacement thereof,
and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.

 

2.            Registration.

 

(a)            Mandatory
Registration. Not later than the Registration Filing Date, the Company shall file with the Commission a Registration Statement
on Form S-1, Form S-3 or any other appropriate form, relating to the resale by the Holders of all of the Registrable
Securities, and the Company shall use commercially reasonable best efforts to cause such Registration Statement to be declared
effective by the Commission as soon as practicable thereafter, but in no event later than the Effectiveness Deadline and shall
use its best efforts to keep such Registration Statement continuously effective under the Securities Act until the date that all
Registrable Securities covered by such Registration Statement (i) have been sold thereunder, or (ii) may be sold without
volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance
with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a
written opinion letter to such effect, addressed and acceptable to the Company’s transfer agent and the affected Holders
(the “Effectiveness Period”). The registration rights under this Section 2 shall not apply or be available
with respect to securities of the Company held by affiliates (as defined in Rule 405 under the Securities Act) and related
persons (as defined in Rule 404 under the Securities Act) of the Placement Agent or the officers and directors of the Company
and their affiliates.

 

    3

     

    

 

(b)            Allocation
of Registrable Securities. The initial number of Registrable Securities included in any Registration Statement and any increase
in the number of Registrable Securities included therein shall be allocated pro rata among the Holders based on the number of Registrable
Securities held by each Holder at the time the Registration Statement covering such initial number of Registrable Securities or
increase thereof is declared effective by the SEC. In the event that a Holder sells or otherwise transfers any of such Holder’s
Registrable Securities, each transferee shall be allocated a pro rata portion of the then remaining number of Registrable Securities
included in such Registration Statement for such transferor. Any shares of Common Stock included in a Registration Statement and
which remain allocated to any Person which ceases to hold any Registrable Securities covered by such Registration Statement shall
be allocated to the remaining Holders, pro rata based on the number of Registrable Securities then held by such Holders which are
covered by such Registration Statement. In no event shall the Company include any securities other than Registrable Securities
in any Registration Statement without the prior written consent of the Majority Holders.

 

(c)            (1) if
the Commission allows the Registration Statement to be declared effective at any time before or after the Effectiveness Date, subject
to the withdrawal of certain Registrable Securities from the Registration Statement, and the reason is the Commission’s determination
that (x) the offering of any of the Registrable Securities constitutes a primary offering of securities by the Company, (y) Rule 415
may not be relied upon for the registration of the resale of any or all of the Registrable Securities, and/or (z) a Holder
of any Registrable Securities must be named as an underwriter, the Holders understand and agree the Company may reduce, on a pro
rata basis, the total number of Registrable Securities to be registered on behalf of each such Holder. In any such pro rata
reduction, the number of Registrable Securities to be registered on such Registration Statement will be reduced on a pro rata basis
based on the total number of unregistered Registrable Securities. In addition, any such affected Holder shall be entitled to Piggyback
Registration rights after the Registration Statement is declared effective by the Commission until such time as: (AA) all Registrable
Securities have been registered pursuant to an effective Registration Statement, (BB) the Registrable Securities may be resold
without restriction pursuant to SEC Rule 144 of the Securities Act or (CC) the Holder agrees to be named as an underwriter
in any such registration statement. The Holders acknowledge and agree the provisions of this paragraph may apply to more than one
Registration Statement; and

 

    4

     

    

 

(2)          For
not more than thirty (30) consecutive days or for a total of not more than sixty (60) days in any twelve (12) month period, the
Company may suspend the use of any prospectus included in any Registration Statement contemplated by this Section in the event
that the Company determines in good faith that such suspension is necessary to (A) delay the disclosure of MNPI concerning
the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the
Company or (B) amend or supplement the affected Registration Statement or the related prospectus so that (i) such Registration
Statement shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein or (ii) such prospectus shall not include an untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements, in the light of the circumstances under which they
were made, not misleading, including in connection with the filing of a post-effective amendment to such Registration Statement
in connection with the Company’s filing of an Annual Report on Form 10-K for any fiscal year (an “Allowed Delay”);
provided, that the Company shall promptly (a) notify each Holder in writing of the commencement of an Allowed Delay, but shall
not (without the prior written consent of an Holder) disclose to such Holder any MNPI giving rise to an Allowed Delay, (b) advise
the Holders in writing to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use
commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable.

 

(d)            Piggyback
Registration Rights. In addition to the Company’s agreement pursuant to Section 2(a) above, if the Company
shall, at any time during the Effectiveness Period or as contemplated pursuant to Section 2(c) and ending when all Registrable
Securities have been sold by Holders, determine (i) to register for sale any of its Common Stock in an underwritten offering,
or (ii) to file a registration statement covering the resale of any shares of the Common Stock held by any of its shareholders
(other than the registration contemplated in Section 2(a) above), the Company shall provide written notice to the Holders,
which notice shall be provided no less than fifteen (15) calendar days prior to the filing of such applicable registration statement
(the “Company Notice”). In that event, the right of any Holder to include the Registrable Securities in such
a registration shall be conditioned upon such Holder’s written request to participate which shall be delivered to the Company
within ten (10) calendar days after the Company Notice, as well as such Holder’s participation in such underwriting
(if applicable, for purposes of this paragraph) and the inclusion of such Holder’s Registrable Securities in the underwriting
to the extent provided herein. All Holders proposing to sell any of their Registrable Securities through such underwriting shall
(together with the Company and any other stockholders of the Company selling their securities through such underwriting) enter
into an underwriting agreement in customary form with the underwriter selected for such underwriting. Notwithstanding anything
herein to the contrary, if the underwriter determines that marketing factors require a limitation on the number of shares of Common
Stock or the amount of other securities to be underwritten, the underwriter may exclude some or all Registrable Securities from
such registration and underwriting. The Company shall so advise all Holders (except those Holders who failed to timely elect to
include their Registrable Securities through such underwriting or have indicated to the Company their decision not to do so), and
indicate to each such Holder the number of shares of Registrable Securities that may be included in the registration and underwriting,
if any. The number of Registrable Securities to be included in such registration and underwriting shall be allocated first to the
Company, then to all other selling stockholders, including the Holders, who have requested to sell in the registration on a pro
rata basis according to the number of shares requested to be included therein. If any Holder disapproves of the terms of any such
underwriting, such Holder may elect to withdraw such Holder’s Registrable Securities therefrom by delivering a written notice
to the Company and the underwriter. A Holder with Registrable Securities included in any registration shall furnish to the Company
such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities
as shall be required in order to comply with any applicable law or regulation in connection with the registration of such Holder’s
Registrable Securities or any qualification or compliance with respect to such Holder’s Registrable Securities and referred
to in this Agreement. The Company shall have the right to terminate or withdraw any registration initiated by it before the effective
date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. Notwithstanding
the foregoing, the Company shall not be required to register any Registrable Securities pursuant to this Section 2(d) that
are eligible for resale pursuant to Rule 144 without restriction (including, without limitation, volume restrictions) or that
are the subject of a then-effective Registration Statement. The Company may postpone or withdraw the filing or the effectiveness
of a piggyback registration at any time in its sole discretion.

 

    5

     

    

 

3.            Registration
Procedures for Registrable Securities. The Company will keep each Holder reasonably advised as to the filing and effectiveness
of the Registration Statement. At its expense with respect to the Registration Statement, the Company will:

 

(a)            prepare
and file with the Commission with respect to the Registrable Securities, a Registration Statement on Form S-1, Form S-3,
or any other form for which the Company then qualifies or which counsel for the Company shall deem appropriate and which form shall
be available for the sale of the Registrable Securities in accordance with the intended methods of distribution thereof, and use
its commercially reasonable efforts to cause such Registration Statement to become effective and shall remain effective during
the Effectiveness Period. Thereafter, the Company shall be entitled to withdraw such Registration Statement and the Holders shall
have no further right to offer or sell any of the Registrable Securities registered for resale thereon pursuant to the respective
Registration Statement (or any prospectus relating thereto);

 

(b)            if
the Registration Statement is subject to review by the Commission, respond in a commercially reasonable manner to all comments
and diligently pursue resolution of any comments to the satisfaction of the Commission;

 

(c)            prepare
and file with the Commission such amendments and supplements to such Registration Statement as may be necessary to keep such Registration
Statement effective during the Effectiveness Period;

 

(d)            furnish,
without charge, to each Holder of Registrable Securities covered by such Registration Statement (i) a reasonable number of
copies of such Registration Statement (including any exhibits thereto other than exhibits incorporated by reference), each amendment
and supplement thereto as such Holder may reasonably request, (ii) such number of copies of the prospectus included in such
Registration Statement (including each preliminary prospectus and any other prospectus filed under Rule 424 of the Securities
Act) as such Holders may reasonably request, in conformity with the requirements of the Securities Act, and (iii) such other
documents as such Holder may require to consummate the disposition of the Registrable Securities owned by such Holder, but only
during the Effectiveness Period;

 

    6

     

    

 

(e)            use
its commercially reasonable efforts to register or qualify such registration under such other applicable securities laws of such
jurisdictions as any Holder of Registrable Securities covered by such Registration Statement reasonably requests and as may be
necessary for the marketability of the Registrable Securities (such request to be made by the time the applicable Registration
Statement is deemed effective by the Commission) and do any and all other acts and things necessary to enable such Holder to consummate
the disposition in such jurisdictions of the Registrable Securities owned by such Holder; provided, that the Company shall
not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify
but for this paragraph, (ii) subject itself to taxation in any such jurisdiction, or (iii) consent to general service
of process in any such jurisdiction.

 

(f)            notify
each Holder of Registrable Securities, the disposition of which requires delivery of a prospectus relating thereto under the Securities
Act, of the happening of any event (as promptly as practicable after becoming aware of such event), which comes to the Company’s
attention, that will after the occurrence of such event cause the prospectus included in such Registration Statement, if not amended
or supplemented, to contain an untrue statement of a material fact or an omission to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading, and the Company shall
promptly thereafter prepare and furnish to such Holder a supplement or amendment to such prospectus (or prepare and file appropriate
reports under the Exchange Act) so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus
shall not contain an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, unless suspension of the use of such prospectus
otherwise is authorized herein or in the event of a Blackout Period, in which case no supplement or amendment need be furnished
(or Exchange Act filing made) until the termination of such suspension or Blackout Period;

 

(g)            comply,
and continue to comply during the Effectiveness Period, in all material respects with the Securities Act and the Exchange Act and
with all applicable rules and regulations of the Commission with respect to the disposition of all securities covered by such
Registration Statement;

 

(h)           as
promptly as practicable after becoming aware of such event, notify each Holder of Registrable Securities being offered or sold
pursuant to the Registration Statement of the issuance by the Commission of any stop order or other suspension of effectiveness
of the Registration Statement;

 

(i)            use
its commercially reasonable efforts to cause all the Registrable Securities covered by the Registration Statement to be quoted
on such Approved Market on which securities of the same class or series issued by the Company are then listed or quoted;

 

(j)            provide
a transfer agent and registrar, which may be a single entity, for the shares of Common Stock registered hereunder;

 

(k)           though
the Registrable Securities will be issued in book entry form, if requested by the Holders, cooperate with the Holders to facilitate
the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant
to the Registration Statement, which certificates shall be free, to the extent permitted by applicable law, of all restrictive
legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders
may request; and

 

    7

     

    

 

(l)            take
all other reasonable actions necessary to expedite and facilitate the disposition by the Holders of the Registrable Securities
pursuant to the Registration Statement.

 

4.            Suspension
of Offers and Sales. Each Holder agrees that, upon receipt of any notice from the Company of the happening of any event of
the kind described in Section 3(f) hereof or of the commencement of a Blackout Period, such Holder shall discontinue
the disposition of Registrable Securities included in the Registration Statement until such Holder’s receipt of the copies
of the supplemented or amended prospectus contemplated by Section 3(f) hereof or notice of the end of the Blackout Period,
and, if so directed by the Company, such Holder shall deliver to the Company (at the Company’s expense) all copies (including,
without limitation, any and all drafts), other than permanent file copies, then in such Holder’s possession, of the prospectus
covering such Registrable Securities current at the time of receipt of such notice.

 

5.            Registration
Expenses. The Company shall pay all expenses in connection with any registration obligation provided herein, including, without
limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable
securities laws, and the fees and disbursements of counsel for the Company and of its independent accountants; provided,
that, in any registration, each party shall pay for its own underwriting discounts and commissions and transfer taxes. Except as
provided in this Section 5 and Section 8, the Company shall not be responsible for the expenses of any attorney or other
advisor employed by a Holder.

 

6.            Assignment
of Rights. The rights under this Agreement shall be automatically assignable by the Holders to any transferee of all or any
portion of such Holder’s Registrable Securities if: (i) the Holder agrees in writing with the transferee or assignee
to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment;
(ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of (a) the
name and address of such transferee or assignee, and (b) the securities with respect to which such registration rights are
being transferred or assigned and (iii) immediately following such transfer or assignment the further disposition of such
securities by the transferee or assignee is restricted under the Securities Act and applicable state securities laws; (iv) at
or before the time the Company receives the written notice contemplated by clause (ii) of this sentence the transferee or
assignee agrees in writing with the Company to be bound by all of the provisions contained herein.

 

7.            Information
by Holder. A Holder with Registrable Securities included in any registration shall furnish to the Company (and any managing
underwriter(s), where applicable) such information regarding itself, the Registrable Securities held by it, the intended method
of disposition of such securities, and such other information as shall be required in order to comply with any applicable law or
regulation in connection with the registration of such Holder’s Registrable Securities or any qualification or compliance
with respect to such Holder’s Registrable Securities and referred to in this Agreement. A form of Selling Stockholder Questionnaire
is attached as Exhibit A hereto.

 

    8

     

    

 

8.            Indemnification.

 

(a)            In
the event of the offer and sale of Registrable Securities under the Securities Act, the Company shall, and hereby does, indemnify
and hold harmless, to the fullest extent permitted by law, each Holder, its directors, officers, partners, each other person who
participates as an underwriter in the offering or sale of such securities, and each other person, if any, who controls or is under
common control with such Holder or any such underwriter within the meaning of Section 15 of the Securities Act, against any
losses, claims, damages or liabilities, joint or several, and expenses to which the Holder or any such director, officer, partner
or underwriter or controlling person may become subject under the Securities Act, the Exchange Act, or any other federal or state
law, insofar as such losses, claims, damages, liabilities or expenses (or actions or proceedings, whether commenced or threatened,
in respect thereof) arise out of or are based upon (1), in the case of any registration statement prepared and filed by the Company
under which Registrable Securities were registered under the Securities Act, if such registration statement contained an untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements
therein not misleading or (2) in the case of any preliminary prospectus, final prospectus or summary prospectus contained
in such registration statement, or any amendment or supplement thereto, if such preliminary prospectus, final prospectus or summary
prospectus includes an untrue statement of a material fact or omits to state a material fact necessary in order to make the statements,
in the light of the circumstances under which they were made, not misleading, or any violation or alleged violation of the Securities
Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange
Act or any state securities law in connection with this Agreement; and the Company shall reimburse the Holder, and each such director,
officer, partner, underwriter and controlling person for any legal or any other expenses reasonably incurred by them in connection
with investigating, defending or settling any such loss, claim, damage, liability, action or proceeding; provided, that
such indemnity agreement found in this Section 8(a) shall in no event exceed the net proceeds from the Offering received
by the Company; and provided further, that the Company shall not be liable in any such case (i) to the extent that
any such loss, claim, damage, liability (or action or proceeding in respect thereof) or expense arises out of or is based upon
an untrue statement in or omission from such registration statement, any such preliminary prospectus, final prospectus, summary
prospectus, amendment or supplement in reliance upon and in conformity with written information furnished to the Company by the
Holder specifically for use in the preparation thereof or (ii) if the person asserting any such loss, claim, damage, liability
(or action or proceeding in respect thereof) who purchased the Registrable Securities that are the subject thereof did not receive
a copy of the preliminary prospectus or the final prospectus (or the final prospectus as amended or supplemented) at or prior to
the written confirmation of the sale of such Registrable Securities to such person because of the failure of such Holder or underwriter
to so provide such preliminary or final prospectus and the untrue statement or omission of a material fact made in such preliminary
prospectus was corrected in the amended preliminary or final prospectus (or the final prospectus as amended or supplemented). Such
indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Holders, or any such
director, officer, partner, underwriter or controlling person and shall survive the transfer of such shares by the Holder.

 

    9

     

    

 

(b)            As
a condition to including Registrable Securities in any registration statement filed pursuant to this Agreement, each Holder agrees
to be bound by the terms of this Section 8 and to indemnify and hold harmless, to the fullest extent permitted by law, the
Company, its directors and officers, and each other person, if any, who controls the Company within the meaning of Section 15
of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which the Company or any such director
or officer or controlling person may become subject under the Securities Act, the Exchange Act, or any other federal or state law,
to the extent arising out of or based solely upon: (x) such Holder’s failure to comply with the prospectus delivery
requirements of the Securities Act or (y)(1), in the case of any registration statement prepared and filed by the Company under
which Registrable Securities were registered under the Securities Act, if such registration statement contained an untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein
not misleading or (2) in the case of any preliminary prospectus, final prospectus or summary prospectus contained in such
registration statement, or any amendment or supplement thereto, such preliminary prospectus, final prospectus or summary prospectus
includes an untrue statement of a material fact or omits to state a material fact necessary in order to make the statements, in
the light of the circumstances under which they were made, not misleading, (i) to the extent, but only to the extent, that
such untrue statement or omission referred to in (y)(1) or (y)(2) above is contained in any information so furnished
in writing by such Holder to the Company specifically for inclusion in the registration statement or such prospectus or (ii) to
the extent that (1) such untrue statements or omissions referred to in (y)(1) or (y)(2) above are based solely upon
information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent
that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and
was reviewed and expressly approved in writing by such Holder expressly for use in the Registration Statement, such prospectus
or such form of prospectus or in any amendment or supplement thereto or (2) in the case of an occurrence of an event of the
type specified in Section 3(f) hereof, the use by such Holder of an outdated or defective prospectus after the Company
has notified such Holder in writing that the prospectus is outdated or defective and prior to the receipt by such Holder of the
advice contemplated in Section 3(f). Each Holder’s obligation to indemnify shall be individual, not joint and several,
and in no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds
received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

(c)            Promptly
after receipt by an indemnified party of notice of the commencement of any action or proceeding involving a claim referred to in
this Section (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made
against an indemnifying party, give written notice to the indemnifying party of the commencement of such action; provided,
that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations
under this Section, except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. In
case any such action is brought against an indemnified party, the indemnifying party shall be entitled to participate in and to
assume the defense thereof, with counsel reasonably satisfactory to such indemnified party and, after notice from the indemnifying
party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to
such indemnified party for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense
thereof, unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying
parties arises in respect of such claim after the assumption of the defenses thereof or the indemnifying party fails to defend
such claim in a diligent manner. If, in such indemnified party’s reasonable judgment a conflict of interest between such
indemnified and indemnifying parties arises in respect of such claim after the assumption of the defenses thereof, the indemnified
party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right
to retain one separate counsel, with the reasonable fees and expenses to be paid by the indemnifying party. No indemnifying party
shall be liable for any settlement of any action or proceeding effected without its consent. No indemnifying party shall, without
the consent of the indemnified party (which consent shall not be unreasonably withheld, conditioned or delayed), consent to entry
of any judgment or enter into any settlement, unless such consent to entry of judgment or settlement includes as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such
claim or litigation. Notwithstanding anything to the contrary set forth herein, and without limiting any of the rights set forth
above, in any event any party shall have the right to retain, at its own expense, counsel with respect to the defense of a claim.

 

    10

     

    

 

(d)            If
an indemnifying party does or is not permitted to assume the defense of an action pursuant to Section 8(c) or in the
case of the expense reimbursement obligation set forth in Sections 8(a) and (b), the indemnification required by Sections
8(a) and 8(b) shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
as and when bills received or expenses, losses, damages, or liabilities are incurred provided that the indemnifying party is provided
appropriate documentation.

 

(e)            If
the indemnification provided for in Section 8(a) or 8(b) is held by a court of competent jurisdiction to be unavailable
to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, the indemnifying party,
in lieu of indemnifying such indemnified party hereunder, shall (i) contribute to the amount paid or payable by such indemnified
party as a result of such loss, liability, claim, damage or expense as is appropriate to reflect the proportionate relative fault
of the indemnifying party on the one hand and the indemnified party on the other (determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission relates to information supplied by the indemnifying
party or the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such untrue statement or omission), or (ii) if the allocation provided by clause (i) above is not permitted
by applicable law or provides a lesser sum to the indemnified party than the amount hereinafter calculated, not only the proportionate
relative fault of the indemnifying party and the indemnified party, but also the relative benefits received by the indemnifying
party on the one hand and the indemnified party on the other, as well as any other relevant equitable considerations. No indemnified
party guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any indemnifying party who was not guilty of such fraudulent misrepresentation. Each Holder’s obligation
to make a contribution pursuant to this Section 8(e) shall be individual, not joint and several, and in no event shall
the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such
Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

9.            Rule 144.
With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC
that may at any time permit the Holders to sell the Registrable Securities to the public without registration, the Company agrees
to use commercially reasonable efforts to: (i) to make and keep public information available as those terms are understood
in SEC Rule 144, (ii) to file with the SEC in a timely manner all reports and other documents required to be filed by
an issuer of securities registered under the Securities Act or the Exchange Act pursuant to SEC Rule 144, (iii) as long
as any Holder owns any Registrable Securities, to furnish in writing upon such Holder’s request a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144 and of the Securities Act and the Exchange Act,
and to furnish to such Holder a copy of the most recent annual or quarterly report of the Company, and such other reports and documents
so filed by the Company as may be reasonably requested in availing such Holder of any rule or regulation of the SEC permitting
the selling of any such Registrable Securities without registration, (iv) with respect to the sale of any Registrable Securities
by a Holder pursuant to SEC Rule 144 and subject to Holder providing necessary documentation to meet the requirements of such
rule, to promptly furnish, without any charge to such Holder, a written legal opinion of its counsel to facilitate such sale and,
if necessary, instruct its transfer agent in writing that it may rely on said written legal opinion of counsel with respect to
said sale and (v) undertake any additional actions commercially necessary to maintain the availability of Rule 144.

 

    11

     

    

 

 

 

10.            Independent
Nature of Each Purchaser’s Obligations and Rights. The obligations of each Purchaser under this Agreement are several
and not joint with the obligations of any other Purchaser, and each Purchaser shall not be responsible in any way for the performance
of the obligations of any other Purchaser under this Agreement. Nothing contained herein and no action taken by any Purchaser pursuant
hereto, shall be deemed to constitute such Purchasers as a partnership, an association, a joint venture, or any other kind of entity,
or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or
the transactions contemplated by this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights,
including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to
be joined as an additional party in any proceeding for such purpose.

 

11.            Miscellaneous.

 

(a)            Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether
of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than
the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction,
such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that
jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    12 

    

    

 

(b)            Remedies.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder
or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. The Company and each
Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it
of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance
in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

 

(c)            Successors
and Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon,
the successors, permitted transferees and assignees, executors and administrators of the parties hereto.

 

(d)            No
Inconsistent Agreements. The Company has not entered, as of the date hereof, and shall not enter, on or after the date of this
Agreement, into any agreement with respect to its securities that would have the effect of impairing the rights granted to the
Holders in this Agreement or otherwise conflicts with the provisions hereof.

 

(e)            Entire
Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the
subjects hereof.

 

(f)            Notices, etc.
All notices or other communications which are required or permitted under this Agreement shall be in writing and sufficient if
delivered by hand, by facsimile transmission, by registered or certified mail, postage pre-paid, by electronic mail, or by courier
or overnight carrier, to the persons at the addresses set forth below (or at such other address as may be provided hereunder),
and shall be deemed to have been delivered as of the date so delivered:

 

If to the Company to:

 

DarioHealth Corp.

8 Ha Tokhen Street

Caesarea Industrial Park, Israel
3088900

Attention:
Attn: Erez Raphael, CEO

Zvi Ben-David, CFO

Email:
erez@mydario.com and zvi@mydario.com

 

With a copy (which shall not constitute
notice) to:

 

Sullivan & Worcester LLP

1633 Broadway, 32nd Floor

New York, New York 10019

Attention: Oded Har-Even, Esq.

Email:
ohareven@sullivanlaw.com If to the Company to:

 

    13 

    

    

 

If to the Purchasers:

 

To each Purchaser at
the address set forth on the signature page hereto or at such other address as any party shall have furnished to the Company
in writing.

 

(g)            Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any Holder, upon any breach or default
of the Company under this Agreement, shall impair any such right, power or remedy of such Holder nor shall it be construed to be
a waiver of any such breach or default, or an acquiescence therein, or of any similar breach or default thereunder occurring; nor
shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.
Any waiver, permit, consent or approval of any kind or character on the part of any Holder of any breach or default under this
Agreement, or any waiver on the part of any Holder of any provisions or conditions of this Agreement, must be in writing and shall
be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, or by law or
otherwise afforded to any holder, shall be cumulative and not alternative.

 

(h)            Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing
such counterparts, and all of which together shall constitute one instrument. In the event that any signature is delivered by facsimile
transmission or electronic transmission via .PDF file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or electronic signature
page were an original thereof.

 

(i)            Severability.
In the case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby.

 

(j)            Amendments.
The provisions of this Agreement may be amended at any time and from time to time, and particular provisions of this Agreement
may be waived, with and only with an agreement or consent in writing signed by the Company and the Majority Holders. The Purchasers
acknowledge that by the operation of this Section, the Majority Holders may have the right and power to diminish or eliminate all
rights of the Holders under this Agreement.

 

[SIGNATURE PAGES FOLLOW]

 

    14 

    

    

 

This Registration Rights
Agreement is hereby executed as of the date first above written.

 

	 	COMPANY:
	 
	 	DarioHealth Corp.
	 	 
	 
	 	By:	 
	 	 	Name:  Erez Raphael
	 	 	Title:    Chief Executive Officer

 

EACH PURCHASER’S SIGNATURE TO THE
SUBSCRIPTION AGREEMENT THAT IS DELIVERED IN CONNECTION WITH THE Offering SHALL CONSTITUTE
SUCH PURCHASER’S SIGNATURE TO THIS REGISTRATION RIGHTS AGREEMENT.

 

    15 

    

    

 

Exhibit A

 

Selling Stockholder Notice and Questionnaire

 

The undersigned beneficial
owner of common stock (the “Registrable Securities”) of DarioHealth Corp., a Delaware corporation (the “Company”),
understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”)
a registration statement (the “Registration Statement”) for the registration and resale under Rule 415
of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance
with the terms of the Registration Rights Agreement (the “Registration Rights Agreement”) to which this document
is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below.
All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.

 

Certain legal consequences
arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders
and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The undersigned beneficial
owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable Securities
owned by it in the Registration Statement.

 

    16 

    

    

 

The undersigned hereby provides the following
information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

		1.	Name.

 

		(a)	Full Legal Name of Selling Stockholder

 

	 	 

 

		(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable
Securities are held:

 

	 	 

 

		(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly
alone or with others has power to vote or dispose of the securities covered by this Questionnaire):

 

	 	 

 

2. Address for Notices to Selling
Stockholder:

 

	 	 
	 	 
	 	 
	 	Telephone:
	 	 
	 	Fax:
	 	 
	 	Contact Person:
	 	 

 

3. Broker-Dealer Status:

 

		(a)	Are you a broker-dealer?

 

Yes
 ̈     No  ̈

 

		(b)	If “yes” to Section 3(a), did you receive your Registrable Securities as compensation
for investment banking services to the Company?

 

    17 

    

    

 

Yes
 ̈     No  ̈

 

		Note:	If “no” to Section 3(b), the Commission’s staff has indicated that you should
be identified as an underwriter in the Registration Statement.

 

		(c)	Are you an affiliate of a broker-dealer?

 

Yes
 ̈     No  ̈

 

		(d)	If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities
in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements
or understandings, directly or indirectly, with any person to distribute the Registrable Securities?

 

Yes
 ̈     No  ̈

 

		Note:	If “no” to Section 3(d), the Commission’s staff has indicated that you should
be identified as an underwriter in the Registration Statement.

 

4. Beneficial Ownership of Securities
of the Company Owned by the Selling Stockholder.

 

Except as set forth below
in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities
issuable pursuant to the Purchase Agreement.

 

		(a)	Type and Amount of other securities beneficially owned by the Selling Stockholder:

 

	 	 
	 	 
	 	 

 

		(b)	Number of shares of Common Stock to be registered pursuant to this Notice for resale:

 

	 	 
	 	 

 

    18 

    

    

 

5. Relationships with the Company:

 

Except as set forth below,
neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the
equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company
(or its predecessors or affiliates) during the past three years.

 

State any exceptions here:

 

	 	 
	 	 
	 	 

 

The undersigned agrees
to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent
to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be
required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.

 

By signing below, the
undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion
of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned
understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration
Statement and the related prospectus and any amendments or supplements thereto.

 

IN WITNESS WHEREOF
the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person
or by its duly authorized agent.

 

	Date:	 	 	Beneficial Owner:	 

 

		 	 	By:	 
		 	 	 	Name:
		 	 	 	Title:

 

PLEASE
FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:

 

    19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]